



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$17.00
Change (%)	▼ 0.3 (1.73%)
Volume	509,642
52 Week Low	\$4.55
Market Cap	\$817,129,862
Rolling EPS	-0.65
PE Ratio	0
Shares Outstanding	47,232,940



Data as of April 26, 2018 12:12 p.m. ET

Recent Press Releases & Upcoming Events

April 23, 2018
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA

There are currently no events scheduled.

April 20, 2018
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

April 2, 2018
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

SEC Filings

Corporate Governance

Filing Date	Form
April 10, 2018	DEF 14A
April 2, 2018	4
April 2, 2018	3
April 2, 2018	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.